|

"3+7" Clinical Trials

2 actively recruiting trials

▲ +1 trial since May 2026

Also known as: IA or DA

Pipeline

Phase 2: 2

Top Sponsors

  • Chinese PLA General Hospital2

Indications

  • Cancer2
  • First Line Therapy1
  • Acute Monocytic Leukemia1
  • Acute Myeloid Leukemia1

Other2 trials

A Multicenter RCT of "3+7" vs Venetoclax + CACAG in Newly Diagnosed Mid/High-Risk AML Patients
Phase 2
Venetoclax Combined With CACAG Regimen Versus "3+7" Regimen in the Treatment of Acute Monocytic Leukemia
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.